Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 51
- Registration Number
- NCT02405858
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
- Conditions
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02380313
Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide
- Conditions
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8
- Registration Number
- NCT02379390
- Locations
- 🇨🇦
Investigational Site Number 124005, Hamilton, Canada
🇨🇦Investigational Site Number 124002, Montreal, Canada
🇨🇦Investigational Site Number 124009, Quebec, Canada
Micro RNAs to Predict Response to Androgen Deprivation Therapy
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 42
- Registration Number
- NCT02366494
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Duke University
- Target Recruit Count
- 38
- Registration Number
- NCT02353715
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
- Conditions
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 75
- Registration Number
- NCT02268175
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 982
- Registration Number
- NCT02257736
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 120
- Registration Number
- NCT02254785
- Locations
- 🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇨🇦Durham Regional Cancer Centre (Lakeridge Health), Oshawa, Ontario, Canada
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT02217566
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
- Conditions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Kenneth Pienta, MD
- Registration Number
- NCT02159690
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.